| Identification | Back Directory | [Name]
1H-Imidazole-4-carboxamide, N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, compd. with benzenesulfonate (1:1) | [CAS]
2055597-39-0 | [Synonyms]
1H-Imidazole-4-carboxamide, N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, compd. with benzenesulfonate (1:1) | [Molecular Formula]
C28H31ClFN7O5S | [MOL File]
2055597-39-0.mol | [Molecular Weight]
632.11 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C, away from moisture | [solubility ]
DMSO : 320 mg/mL (506.24 mM; Need ultrasonic) | [form ]
Solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK. ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations[1].
ERK-IN-3 inhibits the phosphorylation of ERK1/2 substrates such as RSK1, FRA1, and Elk1 in various cell lines[1].ERK-IN-3 showes single-digit nanomolar antiproliferative activity that is selective for MAPK-pathway dependent cancer cell lines[1].
ERK-IN-3 (daily p.o.) inhibits tumor growth in multiple BRAF and KRAS mutant xenograft models in mice and was well tolerated at efficacious doses[1]. | [References]
[1]. Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1). |
|
|